Peak Bggr

8,207 Added | 4 Magazines | 4 Likes | 1 Following | 359 Followers | @Cpizzo721 | Keep up with Peak Bggr on Flipboard, a place to see the stories, photos, and updates that matter to you. Flipboard creates a personalized magazine full of everything, from world news to life’s great moments. Download Flipboard for free and search for “Peak Bggr”

Cramer: Legalization is bad for marijuana pricing—right now, pot stocks look expensive

In honor of 4/20, the unofficial marijuana holiday that falls on April 20, CNBC's Jim Cramer took a look at the state of the red-hot bull market in …

Cannabis

A tale of two deals—ahead of earnings, Biogen move perplexes

Long expected to make a deal, drugmaker Biogen finally did on Friday — just not the deal anyone was expecting.<p>Nearly two years after licensing its …

Biotechnology

Eleven Biotherapeutics (EBIO) in Focus: Stock Moves 8.7% Higher

1 / 2<p>Novartis (NVS) Reports Encouraging Data on MS Candidate<p>Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod …

Multiple Sclerosis

Solid Bio clawing back from clinical hold-stoked selloff; shares up 11%

Solid Biosciences (SLDB +11%) is up, albeit on light volume, as it continues its clawback from the almost 60% drop about a month ago when the FDA …

Biotechnology

Brainstorm Health: Marijuana Health Effects, Biogen Ionis Deal, Google's AI Reach

Happy Friday, readers. This is Sy.<p>Today is April 20, aka 4/20, aka a day now synonymous with entirely too many bad marijuana puns online. The …

Cannabis

Why Dicerna Rocketed Higher Today

Investors are happy the biotech ended a lawsuit hanging over its head.<p>What<p><b>Dicerna Pharmaceuticals</b> (NASDAQ:DRNA) is up 18.6% at 3:31 p.m. EDT after …

Investing

Why Investors Should Build Shares In Bioscience Stocks?

Despite the skittish trading behaviors for bioscience stocks in the prior month, we wish to elucidate why this niche is actually ripe for …

Biotechnology

Is bluebird bio One Step Closer to Its First Commercial Drug?

Interim results for one of its lead gene therapies could suggest an approval in the future<p>Beta thalassemia patients endure a lifetime of blood …

Biotechnology

Are cures bad for the drug business?

<i>This is an excerpt from Second Opinion, a weekly roundup of eclectic and under-the-radar health and medical science news emailed to subscribers every</i> …

Profit

2 'Derisked' Small Biotechs To Buy Now

Today, we look at two biotech names whose pipelines are starting to become "derisked."<p>Both seem undervalued compared to the markets they are …

Biotechnology

NEJM editorial slams design of GSK’s pivotal trial of 3-in-1 COPD drug Trelegy

GlaxoSmithKline has so much riding on the success of its new 3-in-1 COPD drug, Trelegy Ellipta, that last month the company rejiggered its sales and …

Biotechnology

17 Healthy Ways to Cook Chicken in an Instant Pot

Chicken dinners are already easy weeknight meals, but there's a way to make them even easier. All you need is a little help from an Instant Pot. If …

Cooking

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON (Reuters) - Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.<p>The settlement between the two biotech …

Biotechnology

Key events next week - healthcare

Noteworthy events for the week of April 22 - 28 for healthcare investors.<p><b>Monday</b> (4/23): NASH Summit, Boston, MA. Navidea Biopharmaceuticals …

Biotechnology

20 Marijuana Facts for 4/20

The cannabis industry has come a long way since the early 1970s.<p>Today is April 20th. For many, it's not unlike the other 364 calendar days throughout …

Cannabis

Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)

Which stock wins in a head-to-head matchup of these two big pharma companies?<p>Your time horizon matters when it comes to investing.<p><b>GlaxoSmithKline</b>'s …

Biotechnology

Takeda Raises Its Bid for Drugmaker Shire Above $60 Billion

Takeda Pharmaceutical Co. sweetened its offer for drugmaker Shire Plc to more than $60 billion after three prior bids were rejected.<p>Takeda boosted …

Biotechnology

Rounds Report: Crispr Rallied While FDA Developments Could Benefit Gene-Based Innovators

Shares of Crispr continued to trade further North. The management is gearing up the next growth phase by streamlining its team.<p>CRISPR/Cas9 is most …

Biotechnology

Reader Inquiry: What's The Outlook For Atara Biotherapeutics After The Recent Secondary?

The stock has more than doubled since I suggested investors buy shares after January´s secondary offering.<p>Readily available access to capital markets …

Biotechnology

Ionis: Cash, Catalysts And More

Ionis has a billion dollars in cash, along with significant recurring revenue sources.<p>The company has two new therapies up for FDA approval this year.<p>…

Biotechnology

Your Daily Pharma Scoop: Adamas Update, Shire Bidding War, Novartis Results

Adamas continues to have a favorable risk/reward profile.<p>Shire bidding war heats up.<p>Novartis reports Q1 results, showing robust growth in Innovative …

Biotechnology

Ionis Pharmaceuticals' stock soars as Biogen collaboration deal includes $1 billion payment

Shares of Ionis Pharmaceuticals Inc. IONS, -0.39% soared 8.4% in premarket trade Friday, after Biogen Inc. BIIB, -0.75% said it would pay the company …

S&P 500

Top Marijuana Stocks To Consider On The New York Stock Exchange

Today’s date means big celebrations for pot around the world. As medical and recreational marijuana gains increasing legal status in the States and …

Cannabis

China's pharmaceutical industry is poised for major growth

China, the world's manufacturing powerhouse, is moving toward a more value-add economy and there's one major industry where the country could …

Biotechnology

3 Things In Biotech, April 19: Let's Talk Genito-Urinary Cancer

Bristol-Myers keeps the pedal down in renal cancer.<p>AstraZeneca posts signs of life in bladder cancer immunotherapy.<p>Calithera gains fast track in …

Biotechnology

Biogen Pays $1B to Broaden Ionis Pact, Betting More on RNA Drugs

Biogen will pay Ionis Pharmaceuticals $1 billion to expand their current partnership, doubling down on the RNA drugmaking technology that brought the …

Biotechnology

Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More

The biggest news this week was in oncology, hands down. Merck showed that its immunotherapy pembrolizumab (Keytruda) might become a common option for …

Biotechnology

'An Incredible Signal': 4 Experts Weigh In On Positive FDA Panel Vote For GW Pharma (NASDAQ:GWPH)'s Epidiolex

Shares of <b>GW Pharmaceuticals PLC- ADR</b> (NASDAQ: GWPH) were halted Thursday, ahead of a Food and Drug Administration vote on the company's …

Synthetic biology approaches to improving immunotherapy

0000-0003-0319-5416 The AACR 2018 Meeting in Chicago is ending today and has featured the major new results in cancer treatment and immunotherapy …

Immunotherapy

Portfolio Strategy Report: Why Investors Should Build Shares In Bioscience Stocks

Despite the skittish trading behaviors for bioscience stocks in the prior month, we wish to elucidate why this niche is actually ripe for …

Investing